1. Signaling Pathways
  2. MAPK/ERK Pathway
    Stem Cell/Wnt
  3. ERK

ERK

Extracellular signal regulated kinases

ERKs (Extracellular-signal-regulated kinases) are widely expressed protein kinase intracellular signalling molecules that are involved in functions including the regulation of meiosis, mitosis, and postmitotic functions in differentiated cells. Many different stimuli, including growth factors, cytokines, virus infection, ligands for heterotrimeric G protein-coupled receptors, transforming agents, and carcinogens, activate the ERK pathway. In the MAPK/ERK pathway, Ras activates c-Raf, followed by mitogen-activated protein kinase kinase (abbreviated as MKK, MEK, or MAP2K) and then MAPK1/2 (below). Ras is typically activated by growth hormones through receptor tyrosine kinases and GRB2/SOS, but may also receive other signals. ERKs are known to activate many transcription factors, such as ELK1, and some downstream protein kinases. Disruption of the ERK pathway is common in cancers, especially Ras, c-Raf and receptors such as HER2.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-152087
    DCZ19931
    Inhibitor
    DCZ19931 is a potent multi-targeting kinase inhibitor. DCZ19931 has anti-angiogenic effects on ocular neovascularization. DCZ19931 also inhibits ERK1/2-MAPK and p38-MAPK signaling.
    DCZ19931
  • HY-W744699
    Larixol
    Inhibitor
    Larixol is an fMLP inhibitor and also inhibits Src kinase, ERK1/2, p38 and AKT phosphorylation signals in immune regulation. Larixol can interfere with the interaction between the βγ subunit of the fMLP receptor Gi protein and its downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Larixol inhibits fMLP (0.1 μM)-induced superoxide anion production (IC50: 1.98 μM), cathepsin G release (IC50: 2.76 μM), and chemotaxis. Larixol improves neutrophil hyperactivation and reduces inflammation or tissue damage. A series of Larixol derivatives were found to have inhibitory effects on FSGS-related TRPC6 functional mutants.
    Larixol
  • HY-164151
    ERK-IN-8
    Inhibitor
    ERK-IN-8 (compound I-1) is an aniline pyrimidine derivative that acts as an ERK inhibitor. ERK-IN-8 has a strong inhibitory effect on ERK2 in vitro (IC50≤50 nM). ERK-IN-8 can be used in cancer research.
    ERK-IN-8
  • HY-149412
    MHJ-627
    Inhibitor
    MHJ-627 is a potent ERK5 (MAPK7) inhibitor (IC50: 0.91 μM). MHJ-627 promotes the mRNA expression of tumor suppressors and anti-metastatic genes, and promotes cancer cell death.
    MHJ-627
  • HY-145491
    Resolvin D5
    Resolvin D5 is a prolytic mediator (SPM) with anti-inflammatory activity derived from oxidized lipids DHA. Resolvin D5 inhibits Th17 cell differentiation and promotes regulatory T cell differentiation, and inhibits CD4+ T cell proliferation. Resolvin D5 attenuates osteoclast differentiation and interferes with osteoclastogenesis. Resolvin D5 also regulates ERK phosphorylation and nuclear translocation of NF-kappaB. Resolvin D5 could be used in rheumatoid arthritis research.
    Resolvin D5
  • HY-120485
    Raxofelast
    Inhibitor
    Raxofelast (IRFI-016) is an antioxidant agent in various models of ischemia-reperfusion injury. Raxofelast has antiproliferative activity in H2O2-stimulated rat aortic smooth muscle cells. Raxofelast attenuates the activation of mitogen-activating protein kinase (MAPK), ERK kinase 1, 2 (MEK1,2) and protein kinase C (PKC) without affecting Ras expression.
    Raxofelast
  • HY-124514
    UC-857993
    Inhibitor
    UC-857993 is a selective SOS1-Ras inhibitor (Kd=14.7 μM, His6-SOS1cat), suppressing catalytic activity. UC-857993 also inhibits ERK and Ras activation, suppresses the growth of mouse embryonic fibroblasts (MEFs).
    UC-857993
  • HY-156393
    Laxiflorin B
    Inhibitor
    Laxiflorin B, a herbal compound, is a novel selective ERK1/2 inhibitor that has antitumor activity.
    Laxiflorin B
  • HY-N2118R
    Bilobetin (Standard)
    Bilobetin (Standard) is the analytical standard of Bilobetin. This product is intended for research and analytical applications. Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity.
    Bilobetin (Standard)
  • HY-RS08110
    MAPK15 Human Pre-designed siRNA Set A
    Inhibitor

    MAPK15 Human Pre-designed siRNA Set A contains three designed siRNAs for MAPK15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MAPK15 Human Pre-designed siRNA Set A
    MAPK15 Human Pre-designed siRNA Set A
  • HY-149616
    PPM-3
    Degrader
    PPM-3 is a potent and selective PROTAC ERK5 degrader, with an IC50 of 62.4 nM. PPM-3 did not influence tumor cell growth directly. PPM-3 influences tumor development by affecting the differentiation of macrophages.
    PPM-3
  • HY-18849
    ERK2-IN-3
    Inhibitor
    ERK2-IN-3 (compound 2) is a inhibitor of ERK2, and inhibits Erk2WT and Erk2DS1 activation loop phosphorylation, with IC50 of 5 μM and 42 nM, respectively.
    ERK2-IN-3
  • HY-N0202R
    Atractylenolide II (Standard)
    Atractylenolide II (Standard) is the analytical standard of Atractylenolide II. This product is intended for research and analytical applications.
    Atractylenolide II (Standard)
  • HY-RS08111
    Mapk15 Mouse Pre-designed siRNA Set A
    Inhibitor

    Mapk15 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mapk15 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mapk15 Mouse Pre-designed siRNA Set A
    Mapk15 Mouse Pre-designed siRNA Set A
  • HY-145027
    ERK1/2 inhibitor 5
    Inhibitor
    ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 5 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2020238776A1).
    ERK1/2 inhibitor 5
  • HY-142026
    Vitisin A
    Inhibitor
    Vitisin A has antioxidative, anticancer, antiapoptotic, neuroprotective and anti-inflammatory effects. Vitisin A inhibits LPS-induced NO and iNOS production via down-regulation of ERK1/2 and p38 and the NF-κB signal pathway. Vitisin A also inhibits adipocyte differentiation. Vitisin A is a resveratrol tetramer that can be isolated from Vitis vinifera roots.
    Vitisin A
  • HY-135564A
    RK-682
    Inhibitor
    RK-682 is the inhibitor for protein tyrosine phosphatase (PTPase), heparanase, phospholipase A2 and HIV-1 protease. RK-682 inhibits the dephosphorylation of CD45 (IC50 is 54 μM) and VHR (IC50 is 2.0 μM), and thereby inhibits the ERK signaling pathway. RK-682 inhibits the cell viability of cancer cell MGH-U3, T24 and UROtsa with IC50s of 78.2, 43.2 and 145 nM, respectively, arrests the cell cycle at G1/S phase, inhibits the cell migration and autophagy in MGH-U3 and T24.
    RK-682
  • HY-122404
    Xantocillin
    Inhibitor
    Xantocillin (Xanthocillin X) is a marine agent extracted from Penicillium commune, induces autophagy through inhibition of the MEK/ERK pathway.
    Xantocillin
  • HY-W357818
    Glycinexylidide
    Inhibitor
    Glycinexylidide (GX) is the active metabolite of Lidocaine. Lidocaine is a local anesthetic that inhibits sodium channels involving complex voltage and dependence. Lidocaine also reduces the growth, migration and invasion of gastric cancer cells. Glycinexylidide has research potential for use in anesthesia, cancer, and cardiovascular disease.
    Glycinexylidide
  • HY-N3806
    Enniatin B
    Inhibitor 99.10%
    Enniatin B is a Fusarium mycotoxin. Enniatin B inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC50 of 113 μM in an enzyme assay using rat liver microsomes. Enniatins B decreases the activation of ERK (p44/p42).
    Enniatin B
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.